End Stage Renal Disease Clinical Trial
Official title:
Quantifying the Deterioration of Physical Function Along 6 Months in Patients in End Stage Renal Disease
Verified date | April 2017 |
Source | Cardenal Herrera University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Patients undergoing haemodialysis present a decrease in physical function, but little is
known about the rate at which function decreases.
The purpose of this study is quantifying the nature and degree of functional deterioration
experienced by stage 5 chronic kidney disease patients during a six month period of
maintenance haemodialysis therapy.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - people under hemodialysis treatment at least 3 months - be medicable stable - complete all the physical tests Exclusion Criteria: - heart stroke in the previous 6 weeks of the study - inferior limb amputation without artificial aids - cerebral vascular disease (ictus, ischemic) - disability to complete functional tests |
Country | Name | City | State |
---|---|---|---|
Spain | Universidad CEU Cardenal Herrera | Moncada | Valencia |
Lead Sponsor | Collaborator |
---|---|
Cardenal Herrera University |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline Short Physical Performance Battery at 6 months | Assess lower extremity, which includes objective performance-based measure of balance (side-by-side, semi-tanden and tandem), endurance (4m gait speed) and strength (five chair stands). Each component was scored from 0 to 4 and when summed yielded Short Physical Performance Battery scores between 0 (poor) and 12 (best). | At the beginning of the study and after 6 months | |
Primary | Change from Baseline One Leg Standing Test at 6 months | Consist in maintain one leg stance for as long as possible. The test was considered normal if the one leg standing time reached 45 seconds. | At the beginning of the study and after 6 months | |
Primary | Change from Baseline Timed Up and Go at 6 months | To stand up from a standard arms chair, walk 3 meters, turn back the cone walk back and sit down to the chair. The time in seconds is record. | At the beginning of the study and after 6 months | |
Primary | Change from Baseline Sit to Stand to Sit 10 and 60 at 6 months | For the Sit To Stand 10 participant has to stand up and sit down 10 times and the time needed is record; while for the Sit to stand to sit 60 the participant consist in measures how many repetition the participant can to stand up and sit down during 60 seconds | At the beginning of the study and after 6 months | |
Primary | Change from Baseline On leg heel rise at 6 months | It measures the strength in the triceps surae in the one leg standing position and has to rise the heel. It measures how many repetitions the participants is can do | At the beginning of the study and after 6 months | |
Primary | Change from Baseline Handgrip strength at 6 months | To measure the amount of strength developed by each hand in kg | At the beginning of the study and after 6 months | |
Primary | Change from Baseline Six Minutes Walking Time at 6 months | To walk the longest distance possible in 6 minutes by walking continuously the 20 or 30 metres indicated on the floor. It measures the distance in meters | At the beginning of the study and after 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
Completed |
NCT01178216 -
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
|
Phase 1/Phase 2 |